Skip to content

Efficacy of Closed-loop Ventilation to Reduced Sleep Disorders

Contribution to the Understanding of the Involvement of Mechanical Ventilation in ICU Patients Sleep Disorders

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02095496
Acronym
SleepICU
Enrollment
16
Registered
2014-03-24
Start date
2014-10-31
Completion date
2015-12-31
Last updated
2016-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Mechanical Ventilatory Failure, Psychosis Associated With Intensive Care

Keywords

sleep, intensive care, mechanical ventilation

Brief summary

Sleep's deficiencies are very common in intensive care. Mechanical ventilation is a known factor in this deterioration.The investigators hypothesize that close-loop ventilation mode (Intellivent-ASV) is able to minimize sleep deterioration, adjusting ventilation to the patient needs.

Detailed description

In intensive care, conventional mechanical ventilation (pressure support) generates apneas and asynchronies during sleep. Intellivent-ASV would be able to avoid apneas, providing controlled cycles when respiratory rate become too low. Moreover, the constant adjustment of ventilatory parameters to the patient needs would avoid asynchronies between the ventilator and the patient ventilatory drive.

Interventions

12 hours of mechanical ventilation with intellivent-ASV

12 hours of mechanical ventilation with pressure support ventilation

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 94 Years
Healthy volunteers
No

Inclusion criteria

* patient under invasive mechanical ventilation since at least 6 hours and for expected at least 48 hours duration, including a continuous period of 24h, from 2 p.m. to 2 p.m. the next day. * Age \> 18 years * Body Mass Index \< 40 * informed consent signed by the family

Exclusion criteria

* patient requiring neuo-muscular blocking agent or deep sedation enough to abolish spontaneous ventilatory effort * patient with encephalopathy regardless of origin * Patient with Glasgow coma scale score \< 8 * Patient abusing of drug or alcohol * patient with a contraindication for placement of a nasogastric tube such that sufferers of esophageal or gastric ulcer, tumors, diverticulitis or bleeding varices or patients with sinusitis epistaxis or having recently been operated on the nose or pharynx * Patient with bleeding disorders * Patient with unstable respiratory situation as defined by a arterial oxygen partial pressure and inspired oxygen fraction ratio (PaO2/FiO2) \< 100 mmHg with positive end expiratory pressure (PEEP) \> 12 cmH2O * Patient with unstable hemodynamic situation as defined by Systolic Blood Pressure (SBP) \< 75 mmHg despite a therapeutic optimization * Inclusion in another research protocol submitted to consent

Design outcomes

Primary

MeasureTime frameDescription
Sleep fragmentation index12 hours= number of awakenings and arousals per hour of sleep

Secondary

MeasureTime frameDescription
duration of sleep episodes12 hours
Distribution of the sleep12 hoursdistribution of the sleep during day and night

Other

MeasureTime frameDescription
Sleep's architecture12 hoursproportion of the different phases of sleep (slow waves sleep stage 1, 2, 3 and 4 and Rapid Eye Movement (REM) sleep)
ventilation12 hoursnumber of asynchronies and apneas and ventilatory variability
circadian rhythm6 hoursPlasmatic melatonin dosage

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026